Premium
Ethical review in the pharmaceutical industry.
Author(s) -
Ramsay LE,
Tidd MJ,
Butler JK,
Venning GR
Publication year - 1977
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1977.tb00670.x
Subject(s) - pharmaceutical industry , pace , function (biology) , business , drug industry , vulnerability (computing) , engineering ethics , medicine , clinical pharmacology , pharmacology , engineering , computer science , biology , computer security , geodesy , evolutionary biology , geography
1. There seems no reason why clinical pharmacology studies conducted within the pharmaceutical industry should be exempt from the requirement of ethical review, and independent review in this situation reduces the vulnerability of the company and its employees, in addition to serving its primary function of protecting the volunteer subjects. 2. Experience within one company has shown that independent ethical review need not seriously influence the pace of research. 3. It is important that such committees should be seen to be independent and competent.